Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects
Status:
Completed
Trial end date:
2013-06-25
Target enrollment:
Participant gender:
Summary
This is an open-label, parallel group, single and repeat dose pharmacokinetic (PK) study in
healthy male and female subjects. This study will confirm the PK and safety profile in
Chinese subjects. GSK1605786 is currently in clinical development for the treatment of
Crohn's disease. Subjects will receive one of two GSK1605786 doses (500 mg once daily or
500mg twice daily) within 30 minutes after a meal. The study will consist of single and
repeat dose sessions, with pre-dose and serial PK samples taken up to 72-h post-dose.